Reckitt Benckiser Proposes Sale of E45 Brands to Karo Pharma

By Sabela Ojea

Reckitt Benckiser Group PLC said Friday it is proposing to sell its E45 skincare brand and related sub-brands to Karo Pharma AB for an implied enterprise value of 200 million pounds ($268.2 million).

The consumer-goods company--which houses Dettol, Harpic and Durex among its brands--said E45 generated a combined net revenue of GBP43 million for the year ended Dec. 31, 2020.

"The proposed sale, if completed, would be another step forward in Reckitt's plan to actively manage its portfolio for higher growth," the London-listed company said.

The transaction is expected to be completed in the first quarter of 2022, it said.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

December 24, 2021 02:31 ET (07:31 GMT)

Reckitt Benckiser (PK) (USOTC:RBGLY)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024